TREATMENTS FOR EGFR MUTATION-POSITIVE (M+) NSCLC PATIENTS – A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE
Author(s)
Popat S1, Yang JC2, Lungershausen J3, Griebsch I3, Marten A4, Wu Y5
1Royal Marsden Hospital, London, UK, 2National Taiwan University, Taipei, Taiwan, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 5Guangdong Lung Cancer Institute, Guangzhou, China
OBJECTIVES Lung cancer is one of the most common causes of cancer-related deaths world-wide. Afatinib is an irreversible ErbB family blocker showing superior efficacy in EGFRm+ NSCLC as 1st-line treatment compared to standard-of-care chemotherapy. To date, no head-to-head trial results exist to compare afatinib, gefitinib or erlotinib. Previous NMAs have compared the three treatments on an ITT level, but not by mutation type. This analysis attempts to fill this gap. METHODS Based on the EGFRm+ study network requested by NICE a Bayesian approach NMA was conducted to estimate relative treatment effects of afatinib versus erlotinib and gefitinib for progression free survival (PFS) and overall survival (OS) per mutation type (common mutations: Del19 and L858R). RESULTS
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN8
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Oncology